Protocolo para diagnóstico y tratamiento de sarcomas de tejidos blandos del hospital de Basurto / Protocol for diagnosis and treatment of soft tissue sarcomas at the hospital of Basurto

La preservación de la función en el tratamiento de los sarcomas de tejidos blandos (STB) se consigue por medio de resecciones marginales, reconstrucción de tejidos blandos y terapia adyuvante sin que ello implique un aumento en las tasas de recidiva local, de metástasis o de mortalidad; exigen un abordaje multidisciplinario por lo que es necesario coordinar, bajo la forma de Comisión, a los diferentes especialistas que intervienen en las fases diagnóstica y terapéutica. Este es un artículo de revisión del diagnóstico y tratamiento de los sarcomas de tejidos blandos con motivo de la presentación del protocolo establecido en el Hospital de Basurto (Bilbao, España), vigente desde febrero de 2001 que intenta asegurar que los pacientes se beneficien de un tratamiento óptimo (AU)

The preservation of the function in the treatment of Soft Tissue Sarcomas (STS) has been achieved by means of marginal resections, reconstruction of soft tissues and adjuvant therapy without it implies an increase in the rates of local relapse, metastasis or mortality. It demands a multidisciplinary orientation for what is necessary to coordinate, under the form of Commission, the different specialists that take part in the diagnostic and therapeutic phases. This is a review article of the diagnosis and treatment of soft tissues sarcomas because of the protocol presentation settled down in the Hospital of Basurto (Bilbao, España), effective from February of 2001, that tries to assure patient’s benefit with optimal care (AU)

Informe de la actividad del comité de tumores de partes blandas del hospital de Basurto / Report of the activity of the soft tissue tumors committee of the hospital of Basurto

La captación, registro y seguimiento de los pacientes que padecen un tumor de partes blandas es un proceso necesario para asegurar que el paciente es tratado, para coordinar, de una forma completa y sin demoras las fases diagnóstica y terapéutica, y para valorar los resultados de los protocolos aplicados. Entre febrero de 2001 y julio de 2002 fueron presentados 106 pacientes en el Comité de Tumores de Partes Blandas (CTPB) del Hospital de Basurto (Bilbao, España). En esta publicación hacemos un informe descriptivo de la actividad de nuestro Comité y de su funcionamiento (AU)

The reception, registration and follow-up of patients that suffer from a soft tissue tumour are a necessary process to assure adecuate treatment of those patients, to coordinate, in a comprehensive way and without delays, the diagnostic and therapeutic steps and to evaluate the results of the applied protocols. Between February 2001 and July 2002, 106 patients were visited at the Soft Tissue Tumours Committee of the Hospital de Basurto (Bilbao, Espa- ña). In this publication we make a description of the patients included in our protocol and a comment on the way of working of the Committee (AU)

Quantitative determination of the loop diuretic bumetanide in urine and pharmaceuticals by high-performance liquid chromatography with amperometric detection.

A high-performance liquid chromatographic method with amperometric detection has been developed for the determination of the diuretic bumetanide using a microBondapak C18 column. The mobile phase consists of a 50:50 acetonitrile-water mixture containing 5mM KH2PO4-K2HPO4 (pH 4.0). The compound is monitored at +1350 mV with an amperometric detector equipped with a glassy carbon working electrode. A liquid-liquid or solid-liquid extraction is done prior to chromatographic analysis in order to avoid the interferences found in the urine matrix. The percentages of recovery obtained are 71%+/-1% for liquid-liquid extraction and 84.2%+/-0.7% for solid-liquid extraction. The method developed has a linear concentration range from 50 to 499 ng/mL with a reproducibility in terms of relative standard deviation of 1.73% and 3.85% for a concentration level of 70 ng/mL and 237 ng/mL, respectively, and a detection limit of 0.25 ng/mL (3:1 signal-to-noise ratio). The method is applied to the determination of bumetanide in pharmaceutical formulations and urine obtained from hypertensive patients and healthy volunteers after the ingestion of a therapeutic dose of Fordiuran (1 mg bumetanide).

Quantitative determination of indapamide in pharmaceuticals and urine by high-performance liquid chromatography with amperometric detection.

A high-performance liquid chromatographic method with amperometric detection for the determination of the diuretic indapamide using a muBondapak C18 column is developed. The mobile phase consists of an acetonitrile-water mixture (45:55, 5 mM) in KH2PO4-K2HPO4 (pH 4.0). The compound is monitored at +1200 mV with an amperometric detector equipped with a glassy carbon working electrode. A liquid-liquid or solid-liquid extraction is performed prior to chromatographic analysis to avoid the interferences found in urine matrix. Percentages of recovery are 88.3 +/- 5.6 and 82.9 +/- 7.8 for liquid-liquid and solid-liquid extraction, respectively. The developed method has a linear concentration range from 25 to 315 ng/mL with a reproducibility in terms of relative standard deviation of 4% for a concentration level of 0.5 microgram/mL and a quantitation limit of 1 ng/mL. The method is applied to the determination of indapamide in tablets and urine obtained from hypertensive patients after the ingestion of Tertensif (indapamide 2.5 mg).